NCT06661811

A Study of CAR-T Cells Targeting Autoimmune Diseases

A Study of CAR-T Cells Targeting B Cell Related Autoimmune Diseases

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Beijing Boren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.

Detailed description

Autoimmune disease refers to the disease in which the immune system reacts to the host's own body and causes damage to tissues and organs. Autoreactive B cells can self-activate and differentiate into plasma cells releasing large amounts of autoantibodies, while they can also present their own antigens to autoimmune T cells, thus activating T cells and promoting the release of inflammatory factors. CAR-T cells can theoretically completely deplete abnormal antibody-producing B cells, allowing immune rebuilding and restoring the patient's normal immune function, achieving drug-free survival, which fully reflects the application prospects of CAR-T therapy in autoimmune disease.

Conditions

• Autoimmune Diseases

Interventions

Type	Name	Description
DRUG	CAR-T	CAR-T cells

Timeline

• Start date: 2024-11-15
• Primary completion: 2028-04-20
• Completion: 2028-06-20
• First posted: 2024-10-28
• Last updated: 2024-10-28

Locations

1 site across 1 country: China